• Journal of radiological science and technology
• /
• v.33 no.3
• /
• pp.239-243
• /
• 2010

Even though clinical use DRE, PSA and TRUS for screening while diagnosing prostate cancer early, however, we cannot achieve to diagnose it accurately by one method. Thus, mutual supplements are strongly required in diagnosis. It means that we should identify relationship between prostate volume and serum PSA under different ages for better diagnosis. The subjects(405 men) visited the department of diagnostic radiology in a general university hospital from January 2008 to December 2008, who was going to take the prostatic evaluation by TRUS. 13 men, who did definite diagnosis of prostate cancer before through biopsy, were excluded in this study. All data were expressed as mean and standard deviations by using SPSS 14.0 package programs and were analyzed by using one-way ANOVA to evaluate the effect of different ages. And Scheffe Post hoc comparison is accomplished in order to make significant difference in prostate volume, PSA and PSAD according to ages. Pearson correlation was used for ages, prostate volume, PSA and PSAD. According to examination, the subjects' prostate volume and serum PSA level increase as person's age. We can see significant difference between group over 70 years and group from 40 and 50 years. Moreover, age, prostate volume and serum PSA have significant positive correlation. Even though we can get variations in serum PSA level by changing prostate volume according to ages, it is worthwhile to mention that more strong association for prostate volume is observed than ages in elevation of serum PSA. Therefore, it is strongly recommended to consider prostate volume weightly when it comes to evaluate for men with elevated PSA level. Finally, TRUS is an excellent extra equipment to diagnose prostate cancer because it can contribute to early diagnose and pertinent treatment of prostate cancer.

• Journal of the Korean Society of Radiology
• /
• v.11 no.5
• /
• pp.407-412
• /
• 2017

This study investigates the correlations between the total prostate volume (TPV), using the prostate specific antigen (PSA) and prostate specific antigen density (PSAD) as the blood test results and transrectal ultrasound (TRUS), and the prostate transition zone volume (PTZV), as well as variables such as age; the findings can be used as clinical indicators. A retrospective analysis was conducted on 68 healthy men in their 30s who underwent TRUS and PSA and PSAD blood tests from June 2007 to April 2016, with no history of treatment in their prostate. Siemens Acuson sequoia 512 and the probe Siemens EC-10C5 Endocavitary were used as the ultrasound equipment. For statistical analysis, SPSS 18.0 was used to calculate the standard deviation and mean of each variable; Pearson's correlation analysis was also performed. The descriptive statistics of the variables were $24.27{\pm}6.60$ for TPV, $6.99{\pm}6.60$ for PTZV, $2.12{\pm}2.76$ for PSA, and $0.281{\pm}0.1$ for PSAD. The coefficients of correlations between PTZV and variables were 0.831 for PSAD, 0.707 for TPV, 0.398 for age, and 0.118 for PSA. While PSA and age were positively correlated, PSAD and TPV were highly correlated. Therefore, PTZV of men in their 30s without underlying diseases can be predicted using PSAD and TPV.

• Biomedical Science Letters
• /
• v.3 no.2
• /
• pp.107-114
• /
• 1997

Recent reports indicate that the clinical usefulness of prostate specific antigen (PSA), particulary in the differentiation of benign prostate hyperplasia from prostate cancer, can be improved by measuring the amount of free PSA in serum. Measuring free PSA is especially useful in attempts to improve diagnositc performance of PSA in the diagnostic gray zone of total PSA. The objective of this study was to develop free PSA assay kit using sandwich microplate enzyme immunoassay format. We chose a test format with polyclonal anti-PSA antibodies coated on the wells and monoclonal anti-free PSA antibodies for quantification to gain higher test sensitivity. We adpoted 10 uL of specimen and 2 hours of first incubation time with detecting antibody for free PSA EIA format using microplate. The within-day and between-day precision (%CV) in the high and low concentration ranges were below 4%. The correlation coefficient between in-house free PSA assay and commercial assay kit was r=0.9965 (slope=0.0984, y intercept=0.0173, N=27). No hook effect was found by 40 ng/mL and correlation coefficient (r) value of the fitted linear regression was over 0.995. The recovery tests were in the range of 98.9∼104.1％ for free PSA. In conclusion, in-house free PSA enzyme immune assay is cost effective, simple and rapid and could be useful for the prognosis after theraphy as well as for the differential diagnosis between prostate cancer and benign prostate hyperplasia.

• Proceedings of the Korean Vacuum Society Conference
• /
• 2007.08a
• /
• pp.364-364
• /
• 2007

• The Journal of the Korea Contents Association
• /
• v.12 no.6
• /
• pp.338-345
• /
• 2012

Benign prostatic hyperplasia (BPH) is increasing in Korea owing to the westernized eating habits and changes in living environment. However, very few studies have been made to determine the standard value of the prostate volume as a diagnostic reference. Also, most of the previous studies have been focusing on the elder population over 40 years old. This study retrospectively analyzes the results of prostate volume measured by transrectal ultrasonography in the healthy Korean men in their 30's who visited our institution's center for health promotion for routine checkups. The mean age of the total of 157 men enrolled was $34.6{\pm}2.9$ years, and the mean prostate volume was $19.4{\pm}4.0ml$. Prostate volume of these men was correlates proportionally to their age, prostate specific antigen, body mass index, body surface area, and abdominal girth. Among these, the strongest correlation is between the prostate volume and the abdominal girth (r=0.317, p<0.001).

• Radiation Oncology Journal
• /
• v.17 no.2
• /
• pp.136-140
• /
• 1999

Purpose : Prostate specific antigen (PSA) is a useful tumor marker, which is widely used as a diagnostic index and predictor of both treatment and follow-up result in prostate cancer. A prospective analysis was carried out to obtain the period of PSA normalization and the half life of PSA and to analyze the factors influencing the period of PSA normalization. The PSA level was checked before and serially after radical radiotherapy. Materials and Method : Twen쇼 patients with clinically localized prostate cancer who underwent radical external beam radiotherapy were enrolled in this study. Accrual period was from April 1993 to May 1998. Median follow-up period was 20 months. Radiotherapy was given to whole pelvis followed by a boost to prostate. Dose range for the whole pelvis was from 45 Gy to 50 Gy and boost dose to prostate, from 14 Gy to 20 Gy. The post-irradiation PSA normal value was under 3.0 ng/ml. The physical examination and serum PSA level evaluation were performed at 3 month interval in the first one year, and then at every 4 to 6 months. Results : PSA value was normalized in nineteen patients (95%) within 12 months. The mean period of PSA normalization was 5.3 (${\pm}$2.7) months. The half life of PSA Of the nonfailing patients was 2.1 (${\pm}$0.9) month. The nadir PSA level Of the nonfailing Patients waS 0.8 (${\pm}$0.5) ng/ml. The period of PSA normalization had the positive correlation with pretreatment PSA level (R$^{2}$=0.468). The nadir PSA level had no definite positive correlation with the pretreatment PSA level (R$^{2}$=0.075). The half life of serum PSA level also had no definite correlation with pretreatment PSA level (R$^{2}$=0.029). Conclusion :The PSA level was mostly normalized within 8 months (85%). If it has not normalized within 12 months, we should consider the residual disease in prostate or distant metastasis. In 2 patients, the PSA level increased 6 months or 20 months before clinical disease was detected. So the serum PSA level can be used as early diagnostic indicator of treatment failure.

• Journal of radiological science and technology
• /
• v.38 no.4
• /
• pp.437-442
• /
• 2015

Accurate volume measurement of the prostate is a significant role in determining the result of diagnosis and treatment of benign prostate hyperplasia. The purpose of this study was to determine, when measuring prostate volume by TRUS, whether location is more accurately determined by transaxial or longitudinal scanning. With reference to the patient's image, it was produced six prostate model. It compares the actual volume and the measurement volume, and find the optimal measurement position of each specific model. Prostate volume measured by TRUS closely correlates with prostate phantom volume. There was no significant difference(p = .156). To measure the accurate volume of prostate with focal protrusion, its length should be measured exclude the protrusions.

• Journal of Korean Biological Nursing Science
• /
• v.22 no.2
• /
• pp.71-80
• /
• 2020

Purpose: The purpose of this study was to review primary research exploring the correlations between the levels of serum testosterone and the prostate-specific antigen (PSA) in healthy men without prostate diseases. Methods: An integrative review was conducted using the Whittemore & Knafle (2005) framework. The keywords, 'testosterone & prostate-specific antigen', 'testosterone & PSA' and 'healthy men' were used to search peer-reviewed publications in six databases. Among 1,959 searched articles, eleven articles were selected after excluding articles that do not meet inclusion criteria. Literature quality was moderate (Level 3). Results: As a result of this study, it was confirmed through the nine articles that healthy adult men showed no significant correlation between the serum testosterone and the PSA. Conversely, two articles presented that the serum PSA correlate positively with the testosterone. In particular, it is inferred that the effect of the serum testosterone and the PSA secreted into a 24-hour circadian rhythm with different amplitudes and slopes would have had great influence. However, it does not consider the factors affecting the testosterone and the PSA, such as race, liver disease, and BMI, so there is insufficient empirical data to clearly explain the relationship between the testosterone and the PSA. Conclusion: The correlation between the serum testosterone and the PSA in healthy adult men is insignificant in relation to the circadian rhythm of the testosterone and the PSA secretion. It is that a large-scale study including various influencing factors using new biochemical indicators such as pro PSA be conducted in the future.

• Journal of Science and Technology Studies
• /
• v.13 no.1
• /
• pp.77-109
• /
• 2013

The global diffusion of Evidence-Based Medicine (EBM) is changing the landscape of medicine and the healthcare system. STS scholars have shown how EBM works when put into practice. In continuing to add to the literature of previous scholars, this paper traces the historical process and debate over Prostate-Specific Antigen (PSA) testing as an early screening test for prostate cancer in the U.S. This study will reveal that both pros and cons of the testing using EBM as a crucial resources of the debate, and in the process both 'flexibly' interpret and mobilize the hierarchy of scientific evidence for EBM despite the fact the hierarchy is imagined to being scientific criteria that is rigid. Furthermore, this paper will argue that this phenomenon, for which EBM currently seems to support the cons side of PSA screening, was constructed in the context of appraisal of the value 'quality of life' in the EBM system. This case study proposes that those who study the debate of medical technology in the EBM era should contextualize and analyze EBM as part of this debate rather than simply taking EBM for granted.

• Journal of the Korean Society of Food Science and Nutrition
• /
• v.43 no.4
• /
• pp.507-515
• /
• 2014

Benign prostatic hyperplasia (BPH), which is commonly found in aging men, is characterized by hyperplasia of prostatic stromal and epithelial cells beginning in the periurethral zone of the prostate. The prevalence of BPH increases in an age-dependent manner. Here, we investigated the protective effects of unripe Rubus occidentalis extracts (UROE) on BPH development using a prostate cancer cell line and testosterone-induced BPH rat model. Experiments using an established hormone-dependent prostate cancer cell line (LNCaP) showed that UROE treatment significantly decreased expression of androgen-related genes, including androgen receptor (AR), prostate specific antigen (PSA), and 5-alpha reductase 2, but not 5-alpha reductase 1, which was also observed in flutamide-treated cells. Further, AR and PSA gene expression was reduced by UROE treatment under androgen-stimulated conditions using dihydrotestosterone (DHT). BPH animals displayed elevated prostate weights. However, UROE as well as finasteride treatment significantly reduced prostate weights and DHT levels compared to testosterone-induced BPH animals. Histopathological analysis also showed that UROE treatment suppressed testosterone-induced prostatic hyperplasia. Taken together, the results suggest that UROE may effectively inhibit the development of BPH and thus may be a useful agent in BPH treatment.